The PARP inhibitor olaparib exhibits dose-dependent inhibition of glioma cell migration by upregulating MTA3 and E-cadherin, downregulating multiple pro-metastatic proteins, and modulating diverse signaling pathways, highlighting its potential as a therapeutic candidate for glioma treatment (72) (see Table 1, Figure 3). The gene discussed is MTA3; the disease is central nervous system cancer.